Reglan Tardive Dyskinesia Settlement Criteria Explained

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Education to Medication Safety

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatment options. Within this broad context, discussions of medication safety and adverse effects have been central, particularly regarding drugs prescribed for gastrointestinal and neurological disorders. One such medication, metoclopramide—commonly known by the brand name Reglan—has been widely used for decades to treat conditions like gastroparesis and acid reflux. Over time, clinical observations and post-market surveillance have identified a significant association between prolonged Reglan use and the development of tardive dyskinesia, a movement disorder characterized by involuntary, repetitive muscle movements. This risk has prompted regulatory warnings and a substantial body of litigation, leading to the establishment of settlement criteria for affected individuals.

Understanding Tardive Dyskinesia and Its Link to Reglan

Tardive dyskinesia (TD) is a hyperkinetic movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. These movements can be disfiguring and disabling, and they may persist even after the causative agent is discontinued (https://pubmed.ncbi.nlm.nih.gov/29433808/). The condition is caused by exposure to dopamine receptor blocking agents, including metoclopramide, the active ingredient in Reglan. Although TD was historically associated with typical antipsychotics, its incidence is similar with atypical antipsychotics and antiemetics such as metoclopramide (https://pubmed.ncbi.nlm.nih.gov/29433808/). Increased prescribing of these agents and low rates of remission have contributed to a rising prevalence of TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). Reglan’s pharmacology involves antagonism of dopamine D2 receptors in the brain, which can lead to abnormal involuntary movements. The mechanistic pathway linking Reglan to TD is well established: chronic dopamine receptor blockade disrupts basal ganglia function, resulting in the hyperkinetic symptoms of TD.

FDA Warnings and Risk Factors for Tardive Dyskinesia

The risk of developing TD increases with the duration of metoclopramide treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, the FDA recommends avoiding treatment with Reglan for longer than 12 weeks. If longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For symptomatic gastroesophageal reflux, the maximum duration of Reglan treatment is also 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The prescribing information for Reglan includes a boxed warning that explicitly states: "Metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning further notes that the risk increases with duration of treatment and total cumulative dosage, and that Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Healthcare providers are instructed to use Reglan for the shortest duration necessary and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these warnings, some patients may have been prescribed Reglan for extended periods without adequate monitoring, leading to harm.

Settlement Criteria for Reglan-Induced Tardive Dyskinesia

Settlement-related considerations for affected patients often hinge on the timeline between exposure to Reglan and the development of documented harm. The risk of TD from metoclopramide is estimated to be low, in the range of 0.1% per 1000 patient years, which is far below previously estimated risks of 1% to 10% suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, certain high-risk groups are more susceptible: elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). For settlement purposes, establishing a clear causal link between Reglan use and TD requires documentation of the duration of exposure, cumulative dosage, and the onset of symptoms. Patients who developed TD after prolonged use—especially beyond the recommended 12-week limit—may have stronger claims, as the FDA warnings emphasize limiting treatment duration. The clinical presentation of TD can be subtle initially, with involuntary movements of the face or tongue, and may progress to involve the trunk and extremities. Metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates the timeline between exposure and documented harm, as patients may not recognize symptoms until they become severe. Once TD is diagnosed, treatment options include VMAT2 inhibitors such as tetrabenazine, which have been FDA-approved for TD (https://pubmed.ncbi.nlm.nih.gov/29433808/). However, TD may be irreversible, and remission rates are low (https://pubmed.ncbi.nlm.nih.gov/29433808/). In summary, the criteria for Reglan TD settlements typically involve evidence of prolonged or high-dose exposure to metoclopramide, development of TD symptoms consistent with the known clinical presentation, and documentation that the prescribing physician did not adhere to FDA warnings regarding treatment duration and monitoring. Patients in high-risk groups, such as elderly females or diabetics, may be particularly vulnerable. The boxed warning on Reglan’s label underscores the manufacturer’s responsibility to communicate risks, and deviations from recommended use may form the basis for legal claims. Affected individuals should consult with a healthcare provider to confirm a TD diagnosis and with legal counsel to evaluate settlement options based on their specific exposure history and harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is tardive dyskinesia and how is it related to Reglan?

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. It is caused by exposure to dopamine receptor blocking agents like metoclopramide, the active ingredient in Reglan. Chronic use of Reglan can disrupt basal ganglia function, leading to TD, which may be irreversible even after stopping the medication.

What are the FDA warnings regarding Reglan and tardive dyskinesia?

The FDA has issued a boxed warning for Reglan stating that metoclopramide can cause tardive dyskinesia, a potentially irreversible serious movement disorder. The risk increases with duration of treatment and total cumulative dosage. Reglan is contraindicated in patients with a history of TD, and healthcare providers are advised to use the shortest duration necessary and monitor for signs of TD.

Who is at higher risk for developing tardive dyskinesia from Reglan?

High-risk groups include elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy. These individuals may have a lower threshold for neurological complications and should be monitored closely if prescribed Reglan.

What criteria are considered for Reglan tardive dyskinesia settlements?

Settlement criteria typically involve evidence of prolonged or high-dose exposure to metoclopramide, development of TD symptoms consistent with clinical presentation, and documentation that the prescribing physician did not adhere to FDA warnings regarding treatment duration and monitoring. Patients who used Reglan beyond the recommended 12-week limit may have stronger claims.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.